BiomarkerLive

Includes a Live Event on 03/26/2021 at 3:30 PM (EDT)

The BiomarkerLIVE webinar series covers the foundational elements of biomarker testing and application in cancer care. Topics include biomarker basics, inherited cancers, cost and coverage, laboratory medicine, and tumor-specific case examples. 

In an era of precision medicine, pathology plays a critical role in the diagnosis and management of cancer and is uniquely positioned at the intersection of multiple points along the cancer care continuum. ACCC invites you to participate in the next live webinar in this series, Pathology 101, on Friday, March 26, 3:30 – 4:30 PM EDT.

Learn more about the role of laboratory medicine professionals and pathologists, including a review of testing techniques and applications as well as lab-specific regulations and their impact on biomarker testing.

Have your question answered in real-time by our expert faculty, including:

Annette S. Kim, MD, PhD, Associate Professor of Pathology, Harvard Medical School; Hematopathologist And Molecular Pathologist, Brigham And Women's Hospital, Boston, MA

Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics, Baylor Sammons Cancer Center; Staff Pathologist, Baylor University Medical Center, Dallas, TX

Gabriel Bien-Willner, MD, PhD, Medical Director, MolDX; Chief Medical Officer, Palmetto GBA

Hossein Borghaei, DO, MS, Professor and Chief, Thoracic Oncology, The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Department of Hematology and Oncology, Fox Chase Cancer Center

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the sessions.

The ACCC BiomarkerLIVE project is supported by AbbVie, AstraZeneca, Lilly Oncology, and Merck & Co., Inc.

You must have an ACCC or state society account to register for this webinar. 

 If You DO NOT Have an Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. 
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.  
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.  
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link. 
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course! 

If You Have an Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button. 
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course! 

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!  

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC

Associate Professor and Program Director Marcella Niehoff School of Nursing Loyola University Chicago

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC, has advanced certification in oncology nursing and is board-certified in advanced genetics nursing. Her areas of expertise are in oncology and genomics, educational preparation of advanced practice nurses, online education, and interprofessional education and practice. Her doctoral dissertation work was supported by the American Cancer Society (doctoral scholarship) and a pre-doctoral fellowship (F31) from the National Cancer Institute. Her doctoral research, examining the interactions between stress and immune responses in women undergoing diagnostic breast biopsy, was funded by the National Cancer Institute, the Oncology Nursing Foundation, and the Chicago Chapter of the Oncology Nursing Society. Additionally, Dr. Friend has experience with educational training grants and currently leads a team of faculty supported by the NCI-sponsored Interprofessional Education Exchange (iPEX) Project, that is developing interprofessional education in palliative care.

Dr. Friend’s main area of clinical scholarship and research interest is in the area of genetics/genomics. She serves on the Genomics Advisory Board for the Oncology Nursing Society and is interested in improving genomic literacy of healthcare educators, students, and clinicians.

Sue Friedman, DVM

Executive Director and Founder, Facing Our Risk of Cancer Empowered (FORCE)

Dr. Sue Friedman, DVM, was practicing small animal medicine in south Florida in 1996 when she was diagnosed "out of the blue" at age 33 with breast cancer. At the time, she was unaware of familial risk factors for hereditary cancer. Reading an article about hereditary breast cancer after completing her treatment, Sue realized that she had several indications for a mutation. She pursued genetic counseling and, in 1997, tested positive for a BRCA2 mutation.

Shocked that her health care team didn't alert her to the possibility of being at high risk, and disappointed at having to make critical treatment decisions while unaware of her mutation, Sue acted so others could benefit from her misfortune. She founded FORCE in 1999 to fill the information void for individuals and families with hereditary cancer and to help them advocate for themselves. After five years as the organization's executive director (while maintaining her own busy practice), Sue left veterinary medicine to direct FORCE full-time. Since then, the organization has become an unequaled source of research, advocacy, support, and information regarding risk management, prevention, and awareness.

In 2004, Sue relocated her husband Dan, son Beau, and FORCE headquarters to Tampa to work more closely with researchers to improve medical options, care, and outcomes for people affected by hereditary cancer. She is a 20-year breast cancer survivor.

Sue is co-author of the book Confronting Hereditary Breast and Ovarian Cancer, which was published by Johns Hopkins Press, February 2012.

Sarah Hamilton, MS, CGC

Genetic Counselor, Invitae

Sarah Hamilton, MS, CGC, is a certified genetic counselor with over seven years of experience. Sarah began her career as a clinical genetic counselor in Christchurch, New Zealand and worked in a hereditary gastrointestinal cancer clinic. During that time, she developed expertise in the management of Lynch Syndrome and polyposis syndromes. She returned to the United States in May 2019 and is now working for Invitae on their Clinical Consultation Services team. Sarah remains particularly interested in the ever-evolving field of cancer genetics and welcomes any and all opportunities to speak about this topic to patients and clinicians.  

Outside of her professional interests, Sarah is an avid skier, hiker, and biker and enjoys doing all of these activities near her home in Boulder, Colorado. She also loves to cook, listen to podcasts, and knit.  

Annette S. Kim, MD, PhD

Associate Professor of Pathology, Harvard Medical School; Hematopathologist and Molecular Pathologist, Brigham and Women's Hospital

Dr. Annette S. Kim, MD, PhD, is an Associate Professor of Pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital.  She has prior training in synthetic organic chemistry as well as structural biology and spent several years in the pharmaceutical industry prior to her return to academia. Since returning to clinical practice, she has practices diagnostic hematopathology and molecular pathology, and is the Associate Director of the Center for Advanced Molecular Diagnostics in which role she has directed assay validation and quality assurance. Her research program has focused on the study of myeloid neoplasms, mutational patterns in hematopoietic neoplasms, and test utilization. Her research program has identified diagnostic and prognostic small non-coding RNAs in MDS via next generation sequencing and has defined the role of hypermethylation in the regulation of miRNAs in MDS. She has studied the effects of potential therapeutic compounds on cellular function in miRNA-based models of the MDS and in primary clinical samples using single cell phenotyping by mass cytometry with correlation to the mutational profiles of these samples. In addition, she has experience implementing, receiving funding for, and publishing on efforts in test utilization management, conducting studies on cost effective practice of hematopathology.  She has been an active member of the Association of Molecular Pathology, serving as Chair of several committees and a member of the Executive Committee, Strategic Opportunities Committee, and Board.  She also serves on the College of American Pathologists Molecular Oncology Committee. Through these Societies she has published key papers on myeloid mutational patterns and performance of FDA companion diagnostics and laboratory developed assays, including performance of next generation sequencing assays.

Michelle Shiller, DO, AP/CP, MGP

Co-Medical Director of Genetics, Baylor Sammons Cancer Center; Staff Pathologist, Baylor University Medical Center

Dr. Michelle Shiller, DO, AP/CP, MGP, is board certified in Anatomic, Clinical, and Molecular Genetic Pathology following completion of residency at Baylor University Medical Center in Dallas, Texas and fellowship at The Mayo Clinic in Rochester, Minnesota. Upon completion of training, Dr. Shiller established practice with Pathologists Biomedical Laboratories in Dallas, Texas, who services the majority of the DFW metroplex Baylor Scott and White Hospitals. As a result of her experience, she has served on multiple committees considering testing implementation and utilization. Dr. Shiller serves on the Quality Committee for the Baylor Sammons Cancer Center, and as Assistant Medical Director for Cancer Genetics, primarily focusing on germline cancer predisposition, as well as Co-Assistant Medical Director for the Division of Molecular Medicine and Pathology. Finally, within the Baylor Scott and White system, Dr. Shiller has also served on the Baylor Medical Board. 

As a result of the emerging field of molecular pathology, Dr. Shiller has provided many educational forums to empower providers and break down barriers to implementation. This has led to Dr. Shiller securing the opportunity and embracing her passion for educating individuals at a larger scale, through the support and encouragement of many pharmaceutical companies in the form of speaking programs, video recordings, webinars and content development. Consequently, Dr. Shiller has also served on steering committees and advisory boards for multiple entities. Dr. Shiller is an active member of the Association for Molecular Pathology, and also served to develop a consistent dialogue between molecular pathology and oncology, assisting with developing the ASCO-sponsored Molecular Tumor Board. With a patient-centered focus, quality, accuracy, relevance, timeliness, teamwork and conscientious stewardship of the patient specimen are considerations that Dr. Shiller is inspired to bring to reality with the ongoing integration of molecular diagnostics in the field of oncology. She is excited to partner with the Association of Community Cancer Centers on the Board of Trustees to further impact patient care positively with this focus. 

Gabriel Bien-Willner, M.D., PhD.

Medical Director, MolDX; Chief Medical Officer, Palmetto GBA

My goal is to fully integrate Genetics and Genomics into the clinical space- to change our approach to cancer care by targeting cancer disease mechanisms to improve patient outcomes. Clinical genomics, through the use of new "Next-Generation" sequencing technologies (NGS) is making this a reality.

Our current focus is on bringing expert clinical interpretation to complex genomics data as a professional service. Current clinical laboratory Next-Gen sequencing test results are simply too complex for most oncologists to fully comprehend. We seek to bridge this gap and provide them with a thorough explanation of the biology of their patient's tumor, as well as relevant targeted treatment options and clinical trials.

I have expertise in NGS clinical and research pipleline development, as well as working with informatics teams to build clinically-relevant systems for complex data annotation and interpretation. I am board certified in Anatomic Pathology and Molecular Genetic Pathology, and have a Ph.D. in Human Molecular Genetics. 

Hossein Borghaei, DO, MS

Professor and Chief, Thoracic Oncology, The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Deprtment of Hematology and Oncology, Fox Chase Cancer Center

Dr. Hossein Borghaei is chief of thoracic medical oncology and director of the Fox Chase Lung Cancer Center in Philadelphia. As a medical oncologist, he uses anti-cancer drugs to treat lung cancer, mesothelioma, lymphoma and other cancers of the chest. In addition, Borghaei is an active researcher with a special interest in developing new cancer therapies, including immunotherapies that fight cancer by targeting unique proteins and genetic pathways in tumors.

Dr. Borghaei completed his medical training at the Philadelphia College of Osteopathic Medicine, graduating in 1996 with a Master of Science degree in microbiology and immunology. He served his residency at Graduate Hospital in Philadelphia and completed a fellowship in hematology-oncology at the Fox Chase Cancer Center before joining its staff full time in 2004.

Dr. Borghaei has served the role of principal and supporting investigator in numerous clinical trials, which are medical studies that aim to evaluate the safety and effectiveness of new drugs and approaches to treatment. He is currently involved in an active phase II trial that evaluates how pleural mesothelioma patients without progressive disease after first-line chemotherapy benefit from maintenance therapy with Alimta.

His research team is also developing naptumomab estafenatox, a monoclonal antibody for lung and other cancers that activates the body’s immune cells to fight the cancer. In addition, Borghaei conducts clinical trials to improve patients’ immune response to cetuximab and other monoclonal antibodies, which increases their effectiveness.

Dr. Borghaei has authored and coauthored numerous scientific journal articles in his career, most focusing on the topic of immunotherapy for lung cancer and lymphoma. He also served as contributing author and panel member for Malignant Pleural Mesothelioma, a 2012 mesothelioma treatment guide published in the Journal of the National Comprehensive Cancer Network (NCCN).

Dr. Borghaei is a member of several professional medical organizations, including the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research.

Additional ACCC Resources to Supplement Your Learning

  • Alternative Payment Models In Cancer Care Online Course —This course builds on the Oncology APM Readiness Assessment first introduced during the APMC workshop. If your cancer center is ready to begin or expand its journey to value-based care—but you are not sure how to get started—these modules can help. In each session, we will dive deeper into each domain and help you determine what is next for your cancer center. We will outline specific next steps and action items your organization can take to begin APM program implementation. In addition, we will also provide real-life examples that correspond to each topic.
  • ACCC members can connect in real-time through members-only virtual discussion forum on ACCCeXchange. Within this forum, ACCC members from every profession involved in cancer care delivery ask and answer questions, discuss common challenges, and share knowledge and experience. Join the discussion and connect with your peers.
  • Looking to become a member of the Association of Community Cancer Centers? Visit our membership page for more information on the types of membership we offer and how you can become involved. If you’re unsure whether or not you’re already a member, please contact our membership department today.
  • The ACCCeLearning portal makes it easy to find education relevant to your needs and interests. Accessible on any device and at any time, courses are available in a variety of formats, so you can listen, watch, read or interact in ways that best suit your needs. Health professionals can claim CME/CPE/CNE credit for all applicable activities. Since you’re already logged in, take a look around today!

Key:

Complete
Failed
Available
Locked
Live Webinar: Pathology 101
Pre-Assessment Survey
1 Question
Pathology 101
03/26/2021 at 3:30 PM (EDT)   |  60 minutes
03/26/2021 at 3:30 PM (EDT)   |  60 minutes
Post-Assessment Survey
7 Questions
On-Demand: Biomarkers 101
Pre-Assessment Survey
1 Question
Biomarkers 101
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin. Introduction to cancer biomarkers, relevant terminology, and implications for cancer care.
Post-Assessment Survey
6 Questions
On-Demand: Genetic vs Genomic – Knowing the Difference for Patients with Inherited Cancers
Pre-Assessment Survey
1 Question
Genetic vs Genomic – Knowing the Difference for Patients with Inherited Cancers
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin. Deep dive into the differences between germline and somatic mutations, with case examples, and presentation of findings from the LUNGevity/FORCE patient survey
Post-Assessment Survey
6 Questions
On-Demand: Biomarker Testing: Cost and Coverage
Pre-Assessment Survey
1 Question
Biomarker Testing: Cost and Coverage
Open to view video.
Open to view video. We review current policies and regulations that drive costs related to biomarker testing.
Post-Assessment Survey
6 Questions